Mesothelioma Pipeline, FDA Approvals, Clinical Trials Development and Companies 2024

DelveInsight's, "Mesothelioma Pipeline Insight 2024" report provides comprehensive insights about 50+ companies and 50+ pipeline drugs in the Mesothelioma pipeline landscape. It covers the Mesothelioma pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Mesothelioma pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Key Takeaways from the Mesothelioma Pipeline Report
• DelveInsight's Mesothelioma pipeline report depicts a robust space with 50+ active players working to develop 50+ pipeline therapies for Mesothelioma treatment.
• The leading companies working in the Mesothelioma Market include Kissei Pharmaceutical Co., Ltd., Novartis Pharmaceuticals, Oncovir, Inc., Sumitomo Pharma Oncology, Bayer, Trizell Ltd, Hutchison Medipharma Limited, Targovax, Polaris Group, Epizyme, Inc., Sanofi, AstraZeneca, Ascentage Pharma Group Inc., Shionogi, Eli Lilly and Company, Incyte Corporation, GlaxoSmithKline, Constellation Pharmaceuticals, Tmunity Therapeutics, Xencor Inc., NGM Biopharmaceuticals Inc., Inhibrx, Inc., VM Oncology, LLC, SOTIO Biotech AG, Atara Biotherapeutics, and others.
• Promising Mesothelioma Pipeline Therapies in the various stages of development include Nivolumab, Ipilimumab, Pemetrexed, MTG201, THOR-707, Pembrolizumab, IAG933, Volrustomig, Carboplatin, and others.
• December 2023: PrECOG LLC announced a study of Phase 3 clinical trials for Durvalumab. The purpose of this study is to see whether adding durvalumab to standard chemotherapy will improve overall survival (OS) in patients with PM.
• December 2023: AstraZeneca announced a study of Phase 3 clinical trials for Volrustomig, Pemetrexed, Carboplatin and Cisplatin. This is a phase III, randomized, open-label, multicenter, global study to determine the efficacy and safety of Volrustomig (MEDI5752) + Carboplatin + Pemetrexed vs the investigator's choice of platinum + Pemetrexed or Nivolumab + Ipilimumab in participants with unresectable pleural mesothelioma.

Request a sample and discover the recent advances in Mesothelioma Treatment Drugs @ Mesothelioma Pipeline Outlook Report- https://www.delveinsight.com/sample-request/mesothelioma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

In the Mesothelioma pipeline report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, Mesothelioma NDA approvals (if any), and product development activities comprising the technology, Mesothelioma collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Mesothelioma Overview
Mesothelioma is a cancer caused by asbestos. It most commonly occurs in the linings of the lungs or the abdomen. The average life expectancy is 18 - 31 months after diagnosis, but prognosis may improve with treatment. Symptoms can include chest pain, shortness of breath and general fatigue.

Find out more about Mesothelioma Therapeutics Assessment @ Mesothelioma Preclinical and Discovery Stage Products- https://www.delveinsight.com/sample-request/mesothelioma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Mesothelioma Emerging Drugs Profile
• MesoPher: Amphera
• Durvalumab: AstraZeneca

Mesothelioma Pipeline Therapeutics Assessment
There are approx. 50+ key companies which are developing the Mesothelioma therapies. The Mesothelioma companies which have their Mesothelioma drug candidates in the most advanced stage, i.e. phase III include, AstraZeneca.

DelveInsight's Mesothelioma pipeline report covers around 50+ products under different phases of clinical development like
• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Mesothelioma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
• Oral
• Parenteral
• Intravenous
• Subcutaneous
• Topical.

Mesothelioma Products have been categorized under various Molecule types such as
• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy

Learn more about the emerging Mesothelioma Pipeline Therapies @ Mesothelioma Clinical Trials Assessment- https://www.delveinsight.com/sample-request/mesothelioma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Scope of the Mesothelioma Pipeline Report
• Coverage- Global
• Mesothelioma Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Mesothelioma Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III Mesothelioma Companies- Kissei Pharmaceutical Co., Ltd., Novartis Pharmaceuticals, Oncovir, Inc., Sumitomo Pharma Oncology, Bayer, Trizell Ltd, Hutchison Medipharma Limited, Targovax, Polaris Group, Epizyme, Inc., Sanofi, AstraZeneca, Ascentage Pharma Group Inc., Shionogi, Eli Lilly and Company, Incyte Corporation, GlaxoSmithKline, Constellation Pharmaceuticals, Tmunity Therapeutics, Xencor Inc., NGM Biopharmaceuticals Inc., Inhibrx, Inc., VM Oncology, LLC, SOTIO Biotech AG, Atara Biotherapeutics, and others.
• Mesothelioma Pipeline Therapies- Nivolumab, Ipilimumab, Pemetrexed, MTG201, THOR-707, Pembrolizumab, IAG933, Volrustomig, Carboplatin, and others.

Dive deep into rich insights for new drugs for Mesothelioma Treatment, Visit @ Mesothelioma Market Drivers and Barriers, and Future Perspective- https://www.delveinsight.com/sample-request/mesothelioma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Table of Content
1. Introduction
2. Executive Summary
3. Mesothelioma: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Mesothelioma - DelveInsight's Analytical Perspective
7. In-depth Commercial Assessment
8. Mesothelioma Collaboration Deals
9. Late Stage Products (Phase III)
10. Durvalumab: AstraZeneca
11. Drug profiles in the detailed report…..
12. Mid Stage Products (Phase II)
13. TRC102: TRACON Pharmaceuticals
14. Drug profiles in the detailed report…..
15. Early Stage Products (Phase I)
16. SG001: CSPC ZhongQi Pharmaceutical Technology
17. Drug profiles in the detailed report…..
18. Preclinical and Discovery Stage Products
19. Drug name: Company name
20. Drug profiles in the detailed report…..
21. Inactive Products
22. Mesothelioma Key Companies
23. Mesothelioma Key Products
24. Mesothelioma- Unmet Needs
25. Mesothelioma- Market Drivers and Barriers
26. Mesothelioma- Future Perspectives and Conclusion
27. Mesothelioma Analyst Views
28. Mesothelioma Key Companies
29. Appendix

For further information on the Mesothelioma Pipeline therapeutics, reach out to Mesothelioma Unmet Needs and Analyst Views- https://www.delveinsight.com/sample-request/mesothelioma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

List of Important Links-

https://www.delveinsight.com/report-store/pulmonary-arterial-hypertension-market
https://www.delveinsight.com/report-store/glaucoma-market
https://www.delveinsight.com/report-store/uveitis-market
https://www.delveinsight.com/report-store/hemophilia-a2030-market
https://www.delveinsight.com/report-store/nephrotic-syndrome-market
https://www.delveinsight.com/report-store/short-bowel-syndrome-market
https://www.delveinsight.com/report-store/complement-3-glomerulopathy-c3g-market
https://www.delveinsight.com/report-store/retinitis-pigmentosa-market
https://www.delveinsight.com/report-store/aplastic-anemia-market
https://www.delveinsight.com/report-store/cystic-fibrosis-market
https://www.delveinsight.com/report-store/heart-failure-market
https://www.delveinsight.com/report-store/peanut-allergy-market
https://www.delveinsight.com/report-store/smoking-cessation-market
https://www.delveinsight.com/report-store/post-operative-pain-management-market
https://www.delveinsight.com/report-store/obstructive-sleep-apnea-osa-market
https://www.delveinsight.com/report-store/glioblastoma-multiforme-gbm-market

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: ybhardwaj@delveinsight.com
Phone: 9650213330
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/consulting/primary-research-services

This release was published on openPR.